Panic disorder: long-term pharmacotherapy and discontinuation

Area of Science:

• Psychiatry
• Clinical Psychology
• Pharmacology

Background:

• Panic disorder (PD) is a chronic condition often requiring long-term management.
• Several medication classes, including MAOIs, SSRIs, and benzodiazepines, are used for PD treatment.
• Understanding the efficacy and long-term risks of these medications is essential for patient care.

Purpose of the Study:

• To compare the effectiveness of different panic disorder medications.
• To evaluate the long-term outcomes of panic disorder treatment, including maintenance therapy.
• To assess the impact of treatment duration and medication tapering on remission rates.

Main Methods:

• A literature review identified effective PD medications (MAOIs, SSRIs, benzodiazepines) and their side effect profiles.
• A double-blind, placebo-controlled trial compared alprazolam and imipramine over an 8-month period (short-term and maintenance phases).
• A subsequent 15-month unblinded follow-up assessed long-term outcomes and treatment adherence.

Main Results:

• Alprazolam demonstrated a more rapid onset of improvement, fewer adverse events, and lower attrition rates compared to imipramine in the short-term phase.
• At 8 months, significantly more patients on alprazolam (62%) were panic-free than those on imipramine or placebo (26%).
• Patients completing long-term maintenance therapy showed significantly higher remission rates (85%) compared to those who did not (55%) at 15-month follow-up.

Conclusions:

• Eight months of treatment can be effective for panic disorder.
• Maintenance treatment does not appear to lead to tolerance, even with benzodiazepines.
• Completion of long-term maintenance therapy is a strong predictor of sustained remission in panic disorder patients.